{"id":1237,"date":"2026-05-06T07:41:11","date_gmt":"2026-05-06T07:41:11","guid":{"rendered":"http:\/\/alliance-co2-solutions.org\/?p=1237"},"modified":"2026-05-06T07:41:11","modified_gmt":"2026-05-06T07:41:11","slug":"mgmt-mrna-expression-was-inhibited-in-a-dose-dependent-manner-in-cells-treated-with-mgmt-kb1-lodn-as-compared-to-cells-treated-with-the-same-amount-of-the-control-oligonucleotides","status":"publish","type":"post","link":"https:\/\/alliance-co2-solutions.org\/?p=1237","title":{"rendered":"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides"},"content":{"rendered":"<p>\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides. results suggest that MGMT-kB1-LODN may provide a novel strategy for cancer therapy. == Introduction == Alkylating agents such as temozolomide (TMZ) are standard first-line chemotherapy recommended for treatment of high-grade gliomas. These drugs are also used in advanced malignant melanoma and other solid neoplasms[1][3]. Currently the treatment of malignant tumors by alkylating agents suffers Rivastigmine tartrate from arrested progress Rivastigmine tartrate due to cancer cell resistance to chemotherapy. Part of this resistance is related to the presence ofO6-methyguanine-DNA-methyltransferase (MGMT), a DNA repair enzyme, that removesO6-methylguanine adducts from the most frequent site of DNA alkylation by chemotherapeutic agents. Therefore, it is not surprising that numerous studies have demonstrated an inverse relationship between MGMT levels and survival of patients treated with alkylating drugs[1],[4][12]. For example, in patients with glioblastoma who are treated with TMZ the inactivation of the MGMT gene via <a href=\"https:\/\/www.adooq.com\/rivastigmine-tartrate.html\">Rivastigmine tartrate<\/a> promoter methylation is associated with improved outcome[13]. At the same time methylation of the MGMT promoter has been found to be an independent prognostic factor by itself[14][17]. These studies indicate that an imposed attenuation of tumor MGMT levels might prove beneficial for cancer treatment. While aiming to enhance the efficacy of alkylating agents by reducing MGMT activity, clinical studies evaluated two pseudosubstrates: O6-benzylguanine (O6-BG) and O6-(4-bromothenyl)-guanine (Lomeguatrib, Patrin, KuDOS Pharmaceuticals, Ltd., Cambridge, UK). The first agent, O6-BG, was administered in combination with diverse alkylating drugs to treat tumors such as gliomas, melanomas, sarcomas, colon cancer and lymphomas[18][25]. Phase I and II clinical trials proved that the combined treatment induced substantial hematologic toxicity warranting dose reduction of the alkylating drugs. Yet, the increased toxicity was not associated with improved efficacy[22],[23],[26],[27]. Similar findings were reported for the other MGMT pseudosubstrate, lomeguatrib, ones administered in combination with TMZ for treatment of melanoma[28][31]. The profound dose-limiting hematologic toxicity of these two MGMT pseudosubstrates is most likely related to the total blockage of MGMT protein synthesis[32]. <a href=\"http:\/\/www.patagonia-argentina.com\/i\/content\/trenes.htm#findel\">Rabbit Polyclonal to hCG beta<\/a> Thus, we hypothesized that mitigation of the transcriptional overexpression of MGMT that spares its basal transcription, might sensitize tumor cells to alkylating agents with limited affliction of the hematopoietic system. Transcriptional control of the MGMT gene is mediated by a non-TATA boxhousekeeping- gene-like promoter. The maximal activity of the promoter lies 5 of the gene from 953 to +202 bp and consists of minimal promoter (69 to +19), and enhancer[33]. The basal activity of MGMT is induced by the 59-bp promoter sequence located at the first exonintron boundary of the MGMT gene. This region is sufficient to provide at least basal levels of MGMT expression bothin vitroandin vivo[34]. In previous studies we have identified, two NF-kappaB binding sites within the enhancer of the MGMT gene[35]. A non-canonical NF-kappaB site at (-)763 and a canonical site at (-)93 that were designated as MGMT-kappaB1 and MGMT-kappaB2, respectively, based on their location. We have also demonstrated that p65\/NF-kappaB homodimer binds specifically to both sites and is involved in MGMT gene regulation[35]. Furthermore, in our previous paper we found that either high constitutive NF-kB activity in gliomas or ectopic p65 stimulated significant cellular resistance to the alkylating agent BCNU, through induction of MGMT expression. On the other Rivastigmine tartrate hand, inhibition of NF-kB activity by the dominant inhibitor &#8211; DNIkappaB sensitized the cells to BCNU[35]. Based on these findings, it is likely that interference with the binding of NF-kappaB to the MGMT enhancer will attenuate Rivastigmine tartrate MGMT expression without impairing the basal expression of MGMT[33]. In the current study we evaluated the effect of such interference bothin-vitroandin-vivo. In addition to the expected effect in enhancing the cytotoxicity of alkylating agent, we have also shown that such interference has independent antineoplastic effect. == Materials and Methods == == Plasmids == For the construction of the luciferase plasmids, four copies of each kappaB site or mutant.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides. results suggest that MGMT-kB1-LODN may provide a novel strategy for cancer therapy. == Introduction == Alkylating agents such as temozolomide (TMZ) are standard first-line chemotherapy recommended for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-1237","post","type-post","status-publish","format-standard","hentry","category-exonucleases","no-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides - MCT1 inhibitor in Alzheimer\u2019s disease<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/alliance-co2-solutions.org\/?p=1237\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides - MCT1 inhibitor in Alzheimer\u2019s disease\" \/>\n<meta property=\"og:description\" content=\"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides. results suggest that MGMT-kB1-LODN may provide a novel strategy for cancer therapy. == Introduction == Alkylating agents such as temozolomide (TMZ) are standard first-line chemotherapy recommended for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/alliance-co2-solutions.org\/?p=1237\" \/>\n<meta property=\"og:site_name\" content=\"MCT1 inhibitor in Alzheimer\u2019s disease\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T07:41:11+00:00\" \/>\n<meta name=\"author\" content=\"editor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"editor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/?p=1237#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/?p=1237\"},\"author\":{\"name\":\"editor\",\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/#\\\/schema\\\/person\\\/a2b0326f36b85c0b32bd36cafe75b703\"},\"headline\":\"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides\",\"datePublished\":\"2026-05-06T07:41:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/?p=1237\"},\"wordCount\":685,\"articleSection\":[\"Exonucleases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/?p=1237\",\"url\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/?p=1237\",\"name\":\"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides - MCT1 inhibitor in Alzheimer\u2019s disease\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/#website\"},\"datePublished\":\"2026-05-06T07:41:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/#\\\/schema\\\/person\\\/a2b0326f36b85c0b32bd36cafe75b703\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/?p=1237#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/alliance-co2-solutions.org\\\/?p=1237\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/?p=1237#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/#website\",\"url\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/\",\"name\":\"MCT1 inhibitor in Alzheimer\u2019s disease\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/#\\\/schema\\\/person\\\/a2b0326f36b85c0b32bd36cafe75b703\",\"name\":\"editor\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4dcc14beeefbe081cae764d647559acc93d9c15b285756a5f3113c02d044c11?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4dcc14beeefbe081cae764d647559acc93d9c15b285756a5f3113c02d044c11?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f4dcc14beeefbe081cae764d647559acc93d9c15b285756a5f3113c02d044c11?s=96&d=mm&r=g\",\"caption\":\"editor\"},\"sameAs\":[\"http:\\\/\\\/alliance-co2-solutions.org\"],\"url\":\"https:\\\/\\\/alliance-co2-solutions.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides - MCT1 inhibitor in Alzheimer\u2019s disease","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/alliance-co2-solutions.org\/?p=1237","og_locale":"en_US","og_type":"article","og_title":"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides - MCT1 inhibitor in Alzheimer\u2019s disease","og_description":"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides. results suggest that MGMT-kB1-LODN may provide a novel strategy for cancer therapy. == Introduction == Alkylating agents such as temozolomide (TMZ) are standard first-line chemotherapy recommended for [&hellip;]","og_url":"https:\/\/alliance-co2-solutions.org\/?p=1237","og_site_name":"MCT1 inhibitor in Alzheimer\u2019s disease","article_published_time":"2026-05-06T07:41:11+00:00","author":"editor","twitter_card":"summary_large_image","twitter_misc":{"Written by":"editor","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/alliance-co2-solutions.org\/?p=1237#article","isPartOf":{"@id":"https:\/\/alliance-co2-solutions.org\/?p=1237"},"author":{"name":"editor","@id":"https:\/\/alliance-co2-solutions.org\/#\/schema\/person\/a2b0326f36b85c0b32bd36cafe75b703"},"headline":"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides","datePublished":"2026-05-06T07:41:11+00:00","mainEntityOfPage":{"@id":"https:\/\/alliance-co2-solutions.org\/?p=1237"},"wordCount":685,"articleSection":["Exonucleases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/alliance-co2-solutions.org\/?p=1237","url":"https:\/\/alliance-co2-solutions.org\/?p=1237","name":"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides - MCT1 inhibitor in Alzheimer\u2019s disease","isPartOf":{"@id":"https:\/\/alliance-co2-solutions.org\/#website"},"datePublished":"2026-05-06T07:41:11+00:00","author":{"@id":"https:\/\/alliance-co2-solutions.org\/#\/schema\/person\/a2b0326f36b85c0b32bd36cafe75b703"},"breadcrumb":{"@id":"https:\/\/alliance-co2-solutions.org\/?p=1237#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/alliance-co2-solutions.org\/?p=1237"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/alliance-co2-solutions.org\/?p=1237#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/alliance-co2-solutions.org\/"},{"@type":"ListItem","position":2,"name":"\ufeffMGMT mRNA expression was inhibited in a dose dependent manner in cells treated with MGMT-kB1-LODN as compared to cells treated with the same amount of the control oligonucleotides"}]},{"@type":"WebSite","@id":"https:\/\/alliance-co2-solutions.org\/#website","url":"https:\/\/alliance-co2-solutions.org\/","name":"MCT1 inhibitor in Alzheimer\u2019s disease","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/alliance-co2-solutions.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/alliance-co2-solutions.org\/#\/schema\/person\/a2b0326f36b85c0b32bd36cafe75b703","name":"editor","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f4dcc14beeefbe081cae764d647559acc93d9c15b285756a5f3113c02d044c11?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f4dcc14beeefbe081cae764d647559acc93d9c15b285756a5f3113c02d044c11?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f4dcc14beeefbe081cae764d647559acc93d9c15b285756a5f3113c02d044c11?s=96&d=mm&r=g","caption":"editor"},"sameAs":["http:\/\/alliance-co2-solutions.org"],"url":"https:\/\/alliance-co2-solutions.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=\/wp\/v2\/posts\/1237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1237"}],"version-history":[{"count":1,"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=\/wp\/v2\/posts\/1237\/revisions"}],"predecessor-version":[{"id":1238,"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=\/wp\/v2\/posts\/1237\/revisions\/1238"}],"wp:attachment":[{"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alliance-co2-solutions.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}